Hoischen Alexander, Ehrler Marion, Fassunke Jana, Simon Matthias, Baudis Michael, Landwehr Christina, Radlwimmer Bernhard, Lichter Peter, Schramm Johannes, Becker Albert J, Weber Ruthild G
Department of Human Genetics, Rheinische Friedrich-Wilhelms-University of Zürich, Zürich, Switerland.
Brain Pathol. 2008 Jul;18(3):326-37. doi: 10.1111/j.1750-3639.2008.00122.x. Epub 2008 Mar 26.
Gangliogliomas are generally benign neuroepithelial tumors composed of dysplastic neuronal and neoplastic glial elements. We screened 61 gangliogliomas [World Health Organization (WHO) grade I] for genomic alterations by chromosomal and array-based comparative genomic hybridization (CGH). Aberrations were detected in 66% of gangliogliomas (mean +/- SEM = 2.5 +/- 0.5 alterations/tumor). Frequent gains were on chromosomes 7 (21%), 5 (16%), 8 (13%), 12 (12%); frequent losses on 22q (16%), 9 (10%), 10 (8%). Recurrent partial imbalances comprised the minimal overlapping regions dim(10)(q25) and enh(12)(q13.3-q14.1). Unsupervised cluster analysis of genomic profiles detected two major subgroups (group I: complete gain of 7 and additional gains of 5, 8 or 12; group II: no major recurring imbalances, mainly losses). A comparison with low-grade gliomas (astrocytomas WHO grade II) showed chromosome 5 gain to be significantly more frequent in gangliogliomas. Interphase fluorescence in situ hybridization (FISH) identified the aberrations to be contained in a subpopulation of glial but not in neuronal cells. Two gangliogliomas and their anaplastic recurrences (WHO grade III) were analyzed. Losses of CDKN2A/B and DMBT1 or a gain/amplification of CDK4 found in the anaplastic tumors were already present in the respective gangliogliomas by array CGH and interphase FISH. In summary, genomic profiling in a large series of gangliogliomas could distinguish genetic subgroups even in this low-grade tumor.
神经节胶质瘤通常是由发育异常的神经元和肿瘤性胶质成分组成的良性神经上皮肿瘤。我们通过染色体和基于芯片的比较基因组杂交(CGH)对61例神经节胶质瘤(世界卫生组织(WHO)I级)进行了基因组改变筛查。在66%的神经节胶质瘤中检测到畸变(平均±标准误=2.5±0.5个畸变/肿瘤)。常见的增益发生在染色体7(21%)、5(16%)、8(13%)、12(12%);常见的缺失发生在22q(16%)、9(10%)、10(8%)。复发性部分失衡包括最小重叠区域dim(10)(q25)和enh(12)(q13.3-q14.1)。基因组图谱的无监督聚类分析检测到两个主要亚组(I组:7号染色体完全增益以及5、8或12号染色体的额外增益;II组:无主要复发性失衡,主要为缺失)。与低级别胶质瘤(WHO II级星形细胞瘤)的比较显示,5号染色体增益在神经节胶质瘤中更为常见。间期荧光原位杂交(FISH)确定畸变存在于胶质细胞亚群而非神经元细胞中。分析了2例神经节胶质瘤及其间变性复发肿瘤(WHO III级)。在间变性肿瘤中发现的CDKN2A/B和DMBT1缺失或CDK4增益/扩增在相应的神经节胶质瘤中通过芯片CGH和间期FISH已经存在。总之,对大量神经节胶质瘤进行基因组分析即使在这种低级别肿瘤中也能区分遗传亚组。